Patents by Inventor Denis Cochonneau

Denis Cochonneau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE TO IMPROVE THE THERAPEUTIC POTENTIAL OF DRUGS
    Publication number: 20230416398
    Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
    Type: Application
    Filed: May 22, 2023
    Publication date: December 28, 2023
    Inventors: Stéphane BIRKLE, Julien FLEURENCE, Sébastien FARAJ, Jean-Marc LE DOUSSAL, Denis COCHONNEAU, Mickaël TERME, Brigitte ASSOULINE
  • Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
    Patent number: 11697689
    Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: July 11, 2023
    Assignees: OGD2 PHARMA, NANTES UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE CANCEROLOGIE DE L'OUEST
    Inventors: Stéphane Birkle, Julien Fleurence, Sébastien Faraj, Jean-Marc Le Doussal, Denis Cochonneau, Mickaël Terme, Brigitte Assouline
  • Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer
    Patent number: 10745489
    Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: August 18, 2020
    Assignees: OGD2 PHARMA, UNIVERSITE DE NANTES
    Inventors: Stephane Birkle, Denis Cochonneau, Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
  • USE OF ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE TO IMPROVE THE THERAPEUTIC POTENTIAL OF DRUGS
    Publication number: 20190375853
    Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
    Type: Application
    Filed: December 5, 2017
    Publication date: December 12, 2019
    Inventors: Stéphane BIRKLE, Julien FLEURENCE, Sébastien FARAJ, Jean-Marc LE DOUSSAL, Denis COCHONNEAU, Mickaël TERME, Brigitte ASSOULINE
  • TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER
    Publication number: 20190023808
    Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.
    Type: Application
    Filed: May 21, 2018
    Publication date: January 24, 2019
    Inventors: Stephane BIRKLE, Denis COCHONNEAU, MyIene DORVILLIUS, Jean-Marc LE DOUSSAL, MickaeI TERME
  • Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
    Patent number: 10000575
    Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: June 19, 2018
    Assignees: OGD2 PHARMA, UNIVERSITE DE NANTES
    Inventors: Stephane Birkle, Denis Cochonneau, Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
  • TARGETING O-ACETYLATED GD2 GANGLIOSIDE AS A NEW THERAPEUTIC AND DIAGNOSTIC STRATEGY FOR CANCER STEM CELLS CANCER
    Publication number: 20160068608
    Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.
    Type: Application
    Filed: April 29, 2014
    Publication date: March 10, 2016
    Inventors: Stephane BIRKLE, Denis COCHONNEAU, MyIene DORVILLIUS, LE DOUSSAL Jean-Marc, MickaeI TERME
  • ANTI-GB3 ANTIBODIES USEFUL IN TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS
    Publication number: 20140044721
    Abstract: The present invention lies in the field of new cancer therapies, more precisely in the field of antiangiogenic compounds. It notably concerns anti-Gb3 antibodies having specific CDR sequences, as well as the use of anti-Gb3 antibodies not coupled to a therapeutic molecule in the treatment of diseases associated with angiogenesis, such as solid tumors.
    Type: Application
    Filed: February 7, 2012
    Publication date: February 13, 2014
    Applicants: INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE, UNIVERSITE DE NANTES
    Inventors: François Paris, Stephane Birkle, Ariane Desselle, Jacques Aubry, Marie-Hélène Gaugler, Denis Cochonneau, Tanguy Chaumette